{
    "id": 6983,
    "fullName": "ARAF S214A",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ARAF S214A does not lie within any known functional domains of the Araf protein (UniProt.org). S214A results in activation of Araf as indicated by increased Erk phosphorylation and transformation of cells in culture (PMID: 24569458).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 369,
        "geneSymbol": "ARAF",
        "terms": [
            "ARAF",
            "A-RAF",
            "ARAF1",
            "PKS2",
            "RAFA1"
        ]
    },
    "variant": "S214A",
    "createDate": "06/02/2015",
    "updateDate": "06/02/2015",
    "referenceTranscriptCoordinates": {
        "id": 90712,
        "transcript": "NM_001654",
        "gDna": "chrX:g.47566721T>G",
        "cDna": "c.640T>G",
        "protein": "p.S214A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6027,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical casestudy, a patient with refractory Erdheim-Chester disease harboring an ARAF S214A mutation had a regression of lesions and a reduction of ARAF S214A in cell-free DNA in the plasma after treatment with Nexavar (sorafenib) (PMID: 26566875).",
            "molecularProfile": {
                "id": 6837,
                "profileName": "ARAF S214A"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 60073,
                "name": "lymphatic system cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5227,
                    "pubMedId": 26566875,
                    "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26566875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6837,
            "profileName": "ARAF S214A",
            "profileTreatmentApproaches": [
                {
                    "id": 5031,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "ARAF S214A"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 90713,
            "transcript": "XM_011543908",
            "gDna": "chrX:g.47566721T>G",
            "cDna": "c.640T>G",
            "protein": "p.S214A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90712,
            "transcript": "NM_001654",
            "gDna": "chrX:g.47566721T>G",
            "cDna": "c.640T>G",
            "protein": "p.S214A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}